Repurposing Screens Identify Rifamycins as Potential Broad-Spectrum Therapy for Multidrug-Resistant Acinetobacter baumannii and Select Agent Microorganisms

• Kaitin KI , DiMasiJA. Measuring the Pace of new drug development in the user fee era. Drug Information Journal34(3) , 673–680 (2000).
   Google Scholar
• Chong CR , SullivanDJ. New uses for old drugs. Nature448 , 645–646 (2007).
   PubMed Web of Science ®Google Scholar
• Netterweld J . Recycling existing drugs. Drug Discov. Devel.16–22 (2008).
   PubMedGoogle Scholar
• Collins FS . Mining for therapeutic gold. Nat. Rev. Drug Discov.10(6) , 395 (2011).
   Google Scholar
• Mody RM , ZaporM, HartzellJD et al. Infectious complications of damage controlorthopedics in war trauma. J. Trauma 67 , 758–761 (2009).
   PubMed Web of Science ®Google Scholar
• Petersen K , RiddleMS, DankoJR et al. Trauma-related Infections in battlefield casualties from Iraq. Ann. Surg. 245 , 803–811 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson E . Burns TC, Hayda RA, Hospenthal DR, Murray CK. infectious complications of open type III tibial fractures among combat casualties. Clin. Infect. Dis.45 , 409–415 (2007).
   PubMed Web of Science ®Google Scholar
• Bossi P , GarinD, GuihotA et al. Bioterrorism: management of major biological agents. Cell Mol. Life Sci. 63 , 2196–2212 (2006).
   PubMed Web of Science ®Google Scholar
• Inglesby TV , DennisDT, HendersonDA et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 283 , 2281–2290 (2000).
   PubMed Web of Science ®Google Scholar
• Dennis DT , InglesbyTV, HendersonDA et al. Tularemia as a biological weapon. JAMA 285(21) , 2763–2773 (2001).
   PubMed Web of Science ®Google Scholar
• Stenseth NC , AtshabarBB, BegonM et al. Plague: past, present, and future. PLoS Med. 5 , e3 (2008).
   PubMed Web of Science ®Google Scholar
• Lee VT , SchneewindO. Protein secretion and the pathogenesis of bacterial infections. Genes Dev.15 , 1725–1752 (2001).
   PubMed Web of Science ®Google Scholar
• Perry RD and Fetherston JD. Yersinia pestis – etiologic agent of plague. Clin. Microbiol. Rev.10 , 35–66 (1997).
   PubMed Web of Science ®Google Scholar
• Saslaw S , EigelsbachHT, WilsonHE, PriorJA, CarhartS. Tularemia vaccine study, I: intracutaneous challenge. Arch. Intern. Med.107 , 121–133 (1961).
   PubMedGoogle Scholar
• Saslaw S , EigelsbachHT, PriorJA, WilsonHE, CarhartS. Tularemia vaccine study, II: respiratory challenge. Arch. Intern. Med.107 , 134–146 (1961).
   Google Scholar
• Turnbull PC . Introduction: anthrax history, disease and ecology. Curr. Top. Microbiol. Immunol.271 , 1–19 (2002) (2002).
   PubMed Web of Science ®Google Scholar
• Passalacqua KD and Bergman NH. Bacillus anthracis: interactions with the host and establishment of inhalational anthrax. Future Microbiol.1 , 397–415 (2006).
   PubMed Web of Science ®Google Scholar
• Chopra S , Torres-OrtizM, HokamaL et al. Repurposing FDA-approved drugs to combat drug resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 65 , 2598–2601 (2010).
   PubMed Web of Science ®Google Scholar
• Gleeson T , PetersenK, MascolaJ. Successful treatment of Acinetobacter meningitis with meropenem and rifampicin. J. Antimicrob. Chemother.56 , 602–603 (2005).
   PubMed Web of Science ®Google Scholar
• Floss HG , Yu T-W. Rifamycin – mode of action, resistance and biosynthesis. Chem. Rev.105 , 621–632 (2005).
   PubMed Web of Science ®Google Scholar
• Drapeau CMJ , GrilliE, PetrosilloN. Rifampin combined regimens for Gram-negative infections: data from the literature. Intl J. Antimicrob. Agents35 , 39–44 (2010).
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E , ZarrilliR. Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance. Future Microbiol.6(4) , 407–422 (2011).
   PubMed Web of Science ®Google Scholar
• Bochner BR . Global phenotypic characterization of bacteria. FEMS Microbiol. Rev.33 , 191–205 (2009).
   PubMed Web of Science ®Google Scholar
• Fukuoka Y , IkedaY, YamashiroY, TakahataM, TodoY, NaritaH. In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob. Agents Chemother.37(3) , 384–392 (1993).
   PubMed Web of Science ®Google Scholar
• Sarkar-Tyson M , AtkinsHS. Antimicrobials for bacterial bioterrorism agents. Future Microbiol.6(6) , 667–676 (2011).
   PubMed Web of Science ®Google Scholar
• Gurgo C . Rifamycins. In: Handbook of Experimental Pharmacology. Born GVR, Cam PE, Caliguiri LA (Eds). Springer-Verlag, NY, USA, 519–555 (1982).
   Google Scholar
• Finland M , GarnerC, WilcoxC, SabathLD. Susceptibility of “Enterobacteria” to penicillins, cephalosporins, lincomycins, erythromycin, and rifampin. J. Infect. Dis.134(Suppl. 1) , S75–S96 (1976).
   PubMed Web of Science ®Google Scholar
• Mandell GL , BennettJE, DolinR. Principles and Practice of Infectious Diseases, 7th Edition. Elsevier, NY, USA (2010).
   Google Scholar

Website

• NIH Clinical Collection. www.nihclinicalcollection.com/index.php?cPath=21
   Google Scholar